T1	CHEM 23 36	antioxidantes
#1	AnnotatorNotes T1	C0003402; Antioxidants; Pharmacologic Substance
T2	PROC 48 70	tratamiento oncológico
#2	AnnotatorNotes T2	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T3	DISO 111 132	cáncer cervicouterino
#3	AnnotatorNotes T3	C0302592; Cervix carcinoma; Neoplastic Process
T4	PROC 163 170	terapia
#4	AnnotatorNotes T4	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T5	PROC 200 213	quimioterapia
#5	AnnotatorNotes T5	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure + C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T6	PROC 216 228	radioterapia
#6	AnnotatorNotes T6	C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T7	DISO 246 267	cáncer cervicouterino
#7	AnnotatorNotes T7	C0302592; Cervix carcinoma; Neoplastic Process
T8	CHEM 338 351	antioxidantes
#8	AnnotatorNotes T8	C0003402; Antioxidants; Pharmacologic Substance
T9	DISO 366 385	efectos secundarios
#9	AnnotatorNotes T9	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T10	PROC 398 426	tratamiento contra el cáncer
#10	AnnotatorNotes T10	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T11	DISO 420 426	cáncer
#11	AnnotatorNotes T11	C0006826; Malignant Neoplasms; Neoplastic Process
T12	CHEM 459 472	antioxidantes
#12	AnnotatorNotes T12	C0003402; Antioxidants; Pharmacologic Substance
T13	PROC 544 551	terapia
#13	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	PROC 559 571	tratamientos
#14	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 597 623	estudio clínico controlado
#15	AnnotatorNotes T15	C0681867; Controlled Study; Research Activity
T16	DISO 641 662	cáncer cervicouterino
#16	AnnotatorNotes T16	C0302592; Cervix carcinoma; Neoplastic Process
T17	CHEM 706 719	antioxidantes
#17	AnnotatorNotes T17	C0003402; Antioxidants; Pharmacologic Substance
T18	PROC 722 729	placebo
#18	AnnotatorNotes T18	C0032042; Placebos; Therapeutic or Preventive Procedure
T19	PROC 735 746	seguimiento
#19	AnnotatorNotes T19	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T20	PROC 787 813	tratamiento antineoplásico
#20	AnnotatorNotes T20	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T21	CHEM 844 857	antioxidantes
#21	AnnotatorNotes T21	C0003402; Antioxidants; Pharmacologic Substance
T22	CHEM 905 916	hemoglobina
#22	AnnotatorNotes T22	C0019046; Hemoglobin; Amino Acid, Peptide, or Protein · Biologically Active Substance
T23	PROC 1006 1026	sobrevida se calculó
#23	AnnotatorNotes T23	C0038953; Survival Analysis; Research Activity
T24	PROC 1107 1118	seguimiento
#24	AnnotatorNotes T24	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T25	CHEM 1245 1258	antioxidantes
#25	AnnotatorNotes T25	C0003402; Antioxidants; Pharmacologic Substance
T26	PROC 1214 1241	tratados con suplementación
#26	AnnotatorNotes T26	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T27	PROC 1313 1324	seguimiento
#27	AnnotatorNotes T27	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T28	PROC 1666 1680	suplementación
#28	AnnotatorNotes T28	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T29	DISO 1502 1512	metástasis
#29	AnnotatorNotes T29	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T30	CHEM 1560 1573	antioxidantes
#30	AnnotatorNotes T30	C0003402; Antioxidants; Pharmacologic Substance
T31	PROC 1594 1601	placebo
#31	AnnotatorNotes T31	C0032042; Placebos; Therapeutic or Preventive Procedure
T32	CHEM 1685 1698	antioxidantes
#32	AnnotatorNotes T32	C0003402; Antioxidants; Pharmacologic Substance
T33	PROC 1983 1997	suplementación
#33	AnnotatorNotes T33	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T34	CHEM 2002 2015	antioxidantes
#34	AnnotatorNotes T34	C0003402; Antioxidants; Pharmacologic Substance
T35	PROC 2027 2038	tratamiento
#35	AnnotatorNotes T35	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T36	DISO 2056 2077	cáncer cervicouterino
#36	AnnotatorNotes T36	C0302592; Cervix carcinoma; Neoplastic Process
T37	PROC 1382 1390	tratados
#37	AnnotatorNotes T37	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T38	PROC 2136 2147	seguimiento
#38	AnnotatorNotes T38	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T39	ANAT 118 132	cervicouterino
#39	AnnotatorNotes T39	C0007874; Cervix Uteri; Body Part, Organ, or Organ Component | C1278987; Entire cervix uteri; Body Part, Organ, or Organ Component
T40	CHEM 175 188	antioxidantes
#40	AnnotatorNotes T40	C0003402; Antioxidants; Pharmacologic Substance
T41	ANAT 253 267	cervicouterino
#41	AnnotatorNotes T41	C0007874; Cervix Uteri; Body Part, Organ, or Organ Component | C1278987; Entire cervix uteri; Body Part, Organ, or Organ Component
T42	DISO 513 519	cáncer
#42	AnnotatorNotes T42	C0006826; Malignant Neoplasms; Neoplastic Process
T43	ANAT 648 662	cervicouterino
#43	AnnotatorNotes T43	C0007874; Cervix Uteri; Body Part, Organ, or Organ Component | C1278987; Entire cervix uteri; Body Part, Organ, or Organ Component
T44	PROC 674 687	suplementados
#44	AnnotatorNotes T44	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T45	PROC 894 916	niveles de hemoglobina
#45	AnnotatorNotes T45	C0518015; Hemoglobin measurement; Laboratory Procedure
T46	PROC 919 927	albúmina
#46	AnnotatorNotes T46	C0201838; Albumin measurement; Laboratory Procedure
T47	ANAT 1146 1160	cervicouterino
#47	AnnotatorNotes T47	C0007874; Cervix Uteri; Body Part, Organ, or Organ Component | C1278987; Entire cervix uteri; Body Part, Organ, or Organ Component
T48	DISO 1139 1160	cáncer cervicouterino
#48	AnnotatorNotes T48	C0302592; Cervix carcinoma; Neoplastic Process
T49	PROC 1272 1279	placebo
#49	AnnotatorNotes T49	C0032042; Placebos; Therapeutic or Preventive Procedure
T50	DISO 1419 1425	cáncer
#50	AnnotatorNotes T50	C0006826; Malignant Neoplasms; Neoplastic Process
T51	DISO 1750 1756	cáncer
#51	AnnotatorNotes T51	C0006826; Malignant Neoplasms; Neoplastic Process
T52	ANAT 2063 2077	cervicouterino
#52	AnnotatorNotes T52	C0007874; Cervix Uteri; Body Part, Organ, or Organ Component | C1278987; Entire cervix uteri; Body Part, Organ, or Organ Component
T53	DISO 2117 2123	cáncer
#53	AnnotatorNotes T53	C0006826; Malignant Neoplasms; Neoplastic Process
T54	PROC 4 18	suplementación
#54	AnnotatorNotes T54	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T56	LIVB 232 241	pacientes
#55	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T58	Spec_cue 442 450	sugieren
T59	Spec_cue 488 497	riesgo de
T60	LIVB 627 636	pacientes
#56	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Duration 751 757	4 años
T64	LIVB 1125 1134	pacientes
#57	AnnotatorNotes T64	C0030705; Patients; Patient or Disabled Group
T65	LIVB 1330 1339	pacientes
#58	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T66	Duration 1348 1354	4 años
T67	LIVB 1372 1381	pacientes
#59	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T69	LIVB 1480 1489	pacientes
#60	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	LIVB 1527 1536	pacientes
#61	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T71	LIVB 1637 1661	pacientes supervivientes
#62	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group + C0206194; Survivors; Patient or Disabled Group
T77	Date 1902 1909	futuros
T78	LIVB 2042 2051	pacientes
#63	AnnotatorNotes T78	C0030705; Patients; Patient or Disabled Group
T80	Duration 2126 2132	4 años
T55	Neg_cue 1713 1715	no
T57	Neg_cue 2078 2080	no
T62	Neg_cue 71 73	no
T63	DISO 96 107	recurrencia
#64	AnnotatorNotes T63	C2825055; Recurrence (disease attribute); Pathologic Function
T68	DISO 498 509	recurrencia
#65	AnnotatorNotes T68	C2825055; Recurrence (disease attribute); Pathologic Function
T72	DISO 864 875	recurrencia
#66	AnnotatorNotes T72	C2825055; Recurrence (disease attribute); Pathologic Function
T73	DISO 1734 1745	recurrencia
#67	AnnotatorNotes T73	C2825055; Recurrence (disease attribute); Pathologic Function
T74	DISO 2101 2112	recurrencia
#68	AnnotatorNotes T74	C2825055; Recurrence (disease attribute); Pathologic Function
T75	DISO 1403 1414	recurrencia
#69	AnnotatorNotes T75	C2825055; Recurrence (disease attribute); Pathologic Function
A2	Assertion T12 Speculated
A6	Assertion T68 Speculated
T76	Neg_cue 1770 1772	no
T79	CONC 1777 1786	evidencia
A4	Assertion T79 Negated
#70	AnnotatorNotes T79	C3887511; Evidence; Idea or Concept 
R3	Negation Arg1:T76 Arg2:T79	
T81	Spec_cue 1813 1825	Posiblemente
T82	CONC 1830 1835	dosis
A5	Assertion T82 Speculated
#71	AnnotatorNotes T82	C0178602; Dosage; Quantitative Concept
T83	Quantifier_or_Qualifier 1836 1844	distinta
A8	Assertion T83 Speculated
T84	Quantifier_or_Qualifier 1866 1871	mejor
A9	Assertion T84 Speculated
T85	Observation 1872 1878	efecto
A10	Assertion T85 Speculated
T86	CONC 473 484	incrementan
A11	Assertion T86 Speculated
#72	AnnotatorNotes T86	C0442805; Increase; Functional Concept
R4	Speculation Arg1:T58 Arg2:T12	
R6	Speculation Arg1:T59 Arg2:T68	
T87	CONC 1716 1726	interfiere
A7	Assertion T87 Negated
#73	AnnotatorNotes T87	C0521102; Interferes with; Functional Concept
R7	Negation Arg1:T55 Arg2:T87	
T88	Observation 80 86	efecto
A3	Assertion T88 Negated
#74	AnnotatorNotes T88	C1518681; Outcome of Therapy; Finding (?)
R1	Negation Arg1:T62 Arg2:T88	
R8	Speculation Arg1:T81 Arg2:T82	
R9	Has_Quantifier_or_Qualifier Arg1:T82 Arg2:T83	
R10	Speculation Arg1:T81 Arg2:T83	
R11	Speculation Arg1:T81 Arg2:T84	
T89	Observation 2087 2094	efectos
A1	Assertion T89 Negated
#75	AnnotatorNotes T89	C0235735; Unexpected therapeutic effect; Finding (?)
R2	Negation Arg1:T57 Arg2:T89	
#76	AnnotatorNotes T85	C0235735; Unexpected therapeutic effect; Finding (?)
R12	Has_Quantifier_or_Qualifier Arg1:T85 Arg2:T84	
R13	Before Arg1:T82 Arg2:T85	
R14	Used_for Arg1:T1 Arg2:T54	
T90	Spec_cue 316 327	sugiere que
T91	CONC 352 361	disminuye
A12	Assertion T91 Speculated
#77	AnnotatorNotes T91	C0547047; Decrease; Quantitative Concept
R15	Speculation Arg1:T90 Arg2:T91	
R17	Causes Arg1:T10 Arg2:T9	
A13	Assertion T8 Speculated
R18	Speculation Arg1:T90 Arg2:T8	
R19	Overlap Arg1:T54 Arg2:T2	
R20	Overlap Arg1:T8 Arg2:T10	
A14	Assertion T9 Speculated
R21	Experiences Arg1:T60 Arg2:T16	
R22	Location_of Arg1:T43 Arg2:T16	
R23	Experiences Arg1:T60 Arg2:T44	
R24	Used_for Arg1:T17 Arg2:T44	
R25	Used_for Arg1:T18 Arg2:T44	
R27	Has_Duration_or_Interval Arg1:T19 Arg2:T61	
R28	After Arg1:T19 Arg2:T20	
T92	Observation 830 836	efecto
#78	AnnotatorNotes T92	C1518681; Outcome of Therapy; Finding (?)
R30	Causes Arg1:T21 Arg2:T92	
R31	Before Arg1:T20 Arg2:T72	
R32	Before Arg1:T16 Arg2:T72	
R33	Before Arg1:T44 Arg2:T72	
R34	Experiences Arg1:T60 Arg2:T20	
R35	Experiences Arg1:T60 Arg2:T92	
R36	Experiences Arg1:T60 Arg2:T72	
T93	CONC 979 1001	prueba de Chi-cuadrado
#79	AnnotatorNotes T93	C0008041; Chi-Square Test; Intellectual Product
T94	CONC 1034 1055	análisis multivariado
#80	AnnotatorNotes T94	C0026777; Multivariate Analysis; Quantitative Concept
T95	CONC 1069 1085	regresión de COX
#81	AnnotatorNotes T95	C0010235; Cox Proportional Hazards Models; Quantitative Concept (?)
R37	Experiences Arg1:T64 Arg2:T48	
R38	Location_of Arg1:T47 Arg2:T48	
T96	Quantifier_or_Qualifier 1164 1188	etapa clínica IIB y IIIB
R39	Has_Quantifier_or_Qualifier Arg1:T48 Arg2:T96	
R40	Used_for Arg1:T25 Arg2:T26	
R41	Experiences Arg1:T64 Arg2:T26	
R45	Experiences Arg1:T64 Arg2:T49	
R46	Before Arg1:T49 Arg2:T27	
R47	Before Arg1:T26 Arg2:T27	
R48	Has_Duration_or_Interval Arg1:T27 Arg2:T66	
R49	Experiences Arg1:T65 Arg2:T26	
R50	Experiences Arg1:T65 Arg2:T48	
R51	Experiences Arg1:T67 Arg2:T37	
R52	Experiences Arg1:T67 Arg2:T75	
R53	Experiences Arg1:T67 Arg2:T50	
R54	Before Arg1:T50 Arg2:T75	
R55	Experiences Arg1:T69 Arg2:T29	
R56	Experiences Arg1:T70 Arg2:T30	
R57	Experiences Arg1:T70 Arg2:T29	
R58	Experiences Arg1:T69 Arg2:T31	
R59	Experiences Arg1:T70 Arg2:T31	
R60	Experiences Arg1:T69 Arg2:T30	
R61	Used_for Arg1:T32 Arg2:T28	
R62	Experiences Arg1:T71 Arg2:T28	
R64	Experiences Arg1:T71 Arg2:T73	
R65	Before Arg1:T51 Arg2:T73	
R66	Experiences Arg1:T71 Arg2:T51	
T97	Observation 1931 1938	efectos
#82	AnnotatorNotes T97	C0235735; Unexpected therapeutic effect; Finding (?)
T98	CONC 1958 1963	dosis
#83	AnnotatorNotes T98	C0178602; Dosage; Quantitative Concept
R67	Before Arg1:T98 Arg2:T97	
R68	Overlap Arg1:T33 Arg2:T35	
R69	Used_for Arg1:T34 Arg2:T33	
R70	Experiences Arg1:T78 Arg2:T33	
R71	Experiences Arg1:T78 Arg2:T35	
R72	Experiences Arg1:T78 Arg2:T36	
R73	Location_of Arg1:T52 Arg2:T36	
R74	Before Arg1:T33 Arg2:T89	
R75	Before Arg1:T53 Arg2:T74	
R76	Experiences Arg1:T78 Arg2:T74	
R77	Experiences Arg1:T78 Arg2:T53	
R78	Overlap Arg1:T74 Arg2:T80	
R79	Has_Duration_or_Interval Arg1:T38 Arg2:T80	
R80	Location_of Arg1:T39 Arg2:T3	
R81	Before Arg1:T3 Arg2:T63	
R82	Used_for Arg1:T40 Arg2:T4	
R83	Overlap Arg1:T4 Arg2:T5	
R84	Overlap Arg1:T4 Arg2:T6	
R85	Experiences Arg1:T56 Arg2:T4	
R86	Experiences Arg1:T56 Arg2:T5	
R87	Experiences Arg1:T56 Arg2:T6	
R88	Experiences Arg1:T56 Arg2:T7	
R89	Location_of Arg1:T41 Arg2:T7	
R90	Speculation Arg1:T90 Arg2:T9	
R91	Before Arg1:T42 Arg2:T68	
R92	Before Arg1:T13 Arg2:T68	
R94	Before Arg1:T14 Arg2:T68	
R96	Combined_with Arg1:T20 Arg2:T21	
R97	Before Arg1:T54 Arg2:T88	
T99	Quantifier_or_Qualifier 1787 1797	suficiente
A15	Assertion T99 Negated
R16	Has_Quantifier_or_Qualifier Arg1:T79 Arg2:T99	
R26	Negation Arg1:T76 Arg2:T99	
#84	AnnotatorNotes T83	C1705242; Different; Qualitative Concept
R5	Before Arg1:T36 Arg2:T74	
#85	AnnotatorNotes T99	C0205410; Sufficient; Qualitative Concept
#86	AnnotatorNotes T84	C0332272; Better; Qualitative Concept
#87	AnnotatorNotes T77	C0016884; Future; Temporal Concept
A16	Experiencer T56 Patient
A17	Experiencer T60 Patient
A18	Experiencer T64 Patient
A19	Experiencer T65 Patient
A20	Experiencer T67 Patient
A21	Experiencer T69 Patient
A22	Experiencer T70 Patient
A23	Experiencer T71 Patient
A24	Experiencer T78 Patient
